Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered in the fourth quarter. The product's sales fell 62% year over year to $198 ...

Sales of both GSK’s and Pfizer’s vaccines for respiratory syncytial virus dropped significantly in the last three months of 2024, compared the same period one year before. In a earnings report ...

Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s ... for treatment-naïve patients with metastatic ...

The Novartis study was specifically in patients who had received prior novel hormonal therapy (NHT) before the mCRPC stage and randomized them to receive a switch of NHT or Pluvicto. The Pfizer ...

Of patients on BRAFTOVI plus cetuximab and mFOLFOX6 ... View the full Prescribing Information. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our ...

With a market cap of $151.6 billion, Pfizer serves millions of patients globally ... of the securities mentioned in this article. All information and data in this article is solely for ...

A phase 3 trial found that a combination of a Pfizer and Astellas drug, enfortumab vedotin, and Merck's drug, pembrolizumab, has significantly improved survival rates for patients with advanced ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer’s future ...